Musavi Maryam, Haftcheshmeh Saeed Mohammadian, Fazel Hadi, Momtazi-Borojeni Amir Abbas
Healthy Ageing Research Center, Neyshabur University of Medical Sciences, Neyshabur, Iran.
Département of Basic Medical Sciences, Neyshabur Université of Médical Sciences, Neyshabur, Iran.
Curr Pharm Des. 2025;31(13):1067-1077. doi: 10.2174/0113816128304401241031094647.
Sepsis, like neutropenic sepsis, is a medical condition in which our body overreacts to infectious agents. It is associated with damage to normal tissues and organs by the immune system, which leads to the spread of inflammation throughout our body. Of note, microRNAs (miRNAs) have been found to have a critical role in the sepsis progression. Such miRNAs are registered in the miRNA databases, such as Gene Expression Omnibus (GEO), with a specific identifier and unique characteristics. There is also computational software, such as TargetScan, that are broadly employed for the analysis of miRNAs, including their identification, target prediction, and functional analysis.
The current study aimed to predict miRNAs involved in sepsis progression. To this end, the GEO database was employed to find the sepsis-related genome profile. Afterward, down-regulated genes were selected for further bioinformatics analysis with the assumption that their decreased expression is associated with an increased sepsis progression. The miRNAs complementary to the selected genes were then predicted using TargetScan software. Based on the current analysis, seven miRNAs, including hsa-miR-325-3p, hsa-miR-146a-3p, hsa-miR-126-5p, hsa-miR-22-3p, hsa-miR-223-3p, hsa-miR-145-5p, and has-miR-181 family, were predicted to participate in sepsis pathogenesis. Among the predicted miRNAs, hsa-miR-325-3p has not been previously predicted or validated to be involved in septic conditions.
Our prediction results showed that hsa-miR-325-3p may target genes implicating in both anti-(ETFB gene) and pro-inflammatory (TCEA1 and PTPN1 genes) responses, suggesting it is an immune hemostasis regulator during sepsis inflammation. Although the role of other predicted miRNAs has been already validated in the sepsis pathogenesis, the current study predicted new targets of these miRNAs, which have not been reported by previous or experimental studies on sepsis and other pathogenic conditions. Notably, other miRNAs, including hsa-miR-146a-3p, hsa-miR-126-5p, hsa-miR-22-3p, hsa-miR-223-3p, and hsa-miR-145-5p were predicted to target genes participating in inflammatory responses, including BLOC1S1, POLR2G, PTPN1, TCEA1, and CCT3.
In conclusion, the results of the present study can provide promising targets as therapeutic and diagnostic tools to treat and manage inflammation sepsis, such as neutropenic sepsis. However, these findings should be further evaluated in experimental studies to find their exact effects and underlying mechanisms.
脓毒症,如中性粒细胞减少性脓毒症,是一种身体对感染因子过度反应的病症。它与免疫系统对正常组织和器官的损伤有关,进而导致炎症在全身扩散。值得注意的是,已发现微小RNA(miRNA)在脓毒症进展中起关键作用。此类miRNA在诸如基因表达综合数据库(GEO)等miRNA数据库中注册,具有特定标识符和独特特征。还有诸如TargetScan等计算软件被广泛用于miRNA分析,包括其鉴定、靶标预测和功能分析。
本研究旨在预测参与脓毒症进展的miRNA。为此,利用GEO数据库查找脓毒症相关的基因组图谱。之后,选择下调基因进行进一步的生物信息学分析,假设其表达降低与脓毒症进展增加有关。然后使用TargetScan软件预测与所选基因互补的miRNA。基于当前分析,预测有7种miRNA,包括hsa-miR-325-3p、hsa-miR-146a-3p、hsa-miR-126-5p、hsa-miR-22-3p、hsa-miR-223-3p、hsa-miR-145-5p和has-miR-181家族,参与脓毒症发病机制。在预测的miRNA中,hsa-miR-325-3p此前未被预测或验证与脓毒症状况有关。
我们的预测结果表明,hsa-miR-325-3p可能靶向涉及抗(ETFB基因)和促炎(TCEA1和PTPN1基因)反应的基因,表明它是脓毒症炎症期间的免疫止血调节因子。尽管其他预测的miRNA在脓毒症发病机制中的作用已得到验证,但本研究预测了这些miRNA的新靶标,这些靶标在先前关于脓毒症和其他致病状况的研究或实验中尚未报道。值得注意的是,其他miRNA,包括hsa-miR-146a-3p、hsa-miR-126-5p、hsa-miR-22-3p、hsa-miR-223-3p和hsa-miR-1,45-5p被预测靶向参与炎症反应的基因,包括BLOC1S1、POLR2G、PTPN1、TCEA1和CCT3。
总之,本研究结果可为治疗和管理炎症性脓毒症(如中性粒细胞减少性脓毒症)提供有前景的治疗和诊断靶点。然而,这些发现应在实验研究中进一步评估,以确定其确切作用和潜在机制。